Key result
Optogenetic left stellate ganglion inhibition reversibly suppresses ischemia-induced ventricular arrhythmias.
Why the study?
Left stellate ganglion (LSG) suppression protects against ventricular arrhythmias (VAs), and optogenetics is a novel technique to reversibly regulate targeted neurons. Whether an optogenetically silenced LSG protects against VAs induced by myocardial ischemia was unknown.
Does optogenetic silencing of the left stellate ganglion prevent myocardial ischemia-induced ventricular arrhythmias in a canine model?
RCT (n=20)
Randomized
Does optogenetic silencing of the left stellate ganglion prevent myocardial ischemia-induced ventricular arrhythmias in a canine model?
This preclinical study demonstrates that optogenetic modulation can reversibly inhibit left stellate ganglion neural activity, thereby increasing electrophysiological stability and protecting against myocardial ischemia-induced ventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
Supports further investigation of sympathetic neuromodulation for ventricular arrhythmias; leaves open clinical applicability pending rigorous trials.
Background Studies have shown that left stellate ganglion (LSG) suppression protects against ventricular arrhythmias (VAs). Optogenetics is a novel technique to reversibly regulate the activity of the targeted neurons. Objectives This study aimed to investigate whether an optogenetically silenced LSG could protect against VAs induced by myocardial ischemia. Methods Adeno-associated virus (AAV) was used as the vector to deliver ArchT, an inhibitory light-sensitive opsin, to the LSG neurons. Twenty male beagles were randomized into the optogenetics group (n = 10, AAV2/9-CAG-ArchT-GFP microinjected into LSG) and control group (n = 10, AAV2/9-CAG-GFP microinjected into LSG). After 4 weeks, the LSG function and neural activity, heart rate variability, ventricular action potential duration, and effective refractory period were measured in the absence or presence of a light-emitting diode illumination (565 nm). Myocardial ischemia was induced by left anterior coronary artery ligation and 1 h of electrocardiography was recorded for VAs analysis. Results ArchT was successfully expressed in all dogs. Transient light-emitting diode illumination significantly suppressed the LSG function, LSG neural activity, and sympathetic nerve indices of heart rate variability as well as prolonged left ventricular effective refractory period and APD90 only in the optogenetics group. Thirty-minute illumination further enhanced these changes in the optogenetics group. Importantly, all of these changes returned to baseline within 2 h after illumination was turned off. Moreover, the ischemia-induced VAs were significantly suppressed by illumination only in the optogenetics group. Conclusions Optogenetic modulation could reversibly inhibit the neural activity of LSG, thereby increasing electrophysiological stability and protecting against myocardial ischemia-induced VAs.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2017) conducted an RCT in Myocardial ischemia-induced ventricular arrhythmias (n=20). Optogenetic modulation of the left stellate ganglion (AAV2/9-CAG-ArchT-GFP + 565 nm LED illumination) vs. Control (AAV2/9-CAG-GFP microinjected into LSG + LED illumination) was evaluated on Myocardial ischemia-induced ventricular arrhythmias and left stellate ganglion neural activity/electrophysiological parameters. Optogenetic inhibition of the left stellate ganglion via 30-min 565 nm illumination significantly suppressed ischemia-induced ventricular arrhythmias in beagles (n=20), reversing within 2 h.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: